Intraoperative Injection of Carbon Nanoparticles

Phase 3Small molecule

SSecond Affiliated Hospital of Xi'an Jiaotong University

Intraoperative Injection of Carbon Nanoparticles is one of 43 small molecule programs targeting Thyroid Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Thyroid CancerActive, not recruiting

Thyroid CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

210 competitors in Thyroid Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Phase 3

12 2

Koselugo

AstraZeneca

Phase 3

3 3

Glucophage

EMD Serono

Phase 3

2 4

Sutent

Pfizer

Phase 2

3 5

Iclusig

Takeda

Phase 2

2 6

Mektovi

Pfizer

Phase 2

1 7

Iressa

AstraZeneca

Phase 2

1 8

Istodax

Teva

Phase 2

1 9

Actos

Takeda

Phase 2

1 10

Stivarga

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thyroid Cancer1 trial

A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.

Recruiting·SSecond Affiliated Hospital of Xi'an Jiaotong University·Phase 3·NCT06791005·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intraoperative Injection of Carbon Nanoparticles. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intraoperative Injection of Carbon Nanoparticles compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intraoperative Injection of Carbon Nanoparticles. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Xi'an Jiaotong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSecond Affiliated Hospital of Xi'an Jiaotong University

Intraoperative Injection of Carbon Nanoparticles

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thyroid Cancer1 trial

References

Drug Info

Quick Facts

Related News